Early Intervention for Language Delay
Trial Summary
What is the purpose of this trial?
Late talkers (LT), representing 10-20% of children under 3, demonstrate hallmark syntax and vocabulary deficits similar to preschoolers with developmental language disorder. While effective and early interventions can mitigate the impact of late talking, not enough is known about its neural basis, yet is needed to inform the design of more individualized interventions. This proposed effort uses neuroimaging, along with behavioral methods, with the goal of better understanding the memory-language mechanisms that underlie learning and late talking, while also considering their association to treatment-related changes in LT.
Will I have to stop taking my current medications?
The trial information does not specify whether participants need to stop taking their current medications.
What data supports the effectiveness of the treatment for late talking?
Research shows that early language interventions, including parent-implemented strategies, can help late talkers improve their language skills. Studies found that children receiving these interventions often show better progress in speaking and understanding language compared to those who do not receive such support.12345
Is the treatment for language delay safe for humans?
How is the Early Intervention for Language Delay treatment different from other treatments for late talking?
This treatment is unique because it involves a parent-implemented approach, where parents actively participate in their child's language development through activities like dialogic book reading, which has shown to improve expressive language skills in both full-term and low-risk preterm late talkers.12357
Research Team
Karla N Washington, PhD
Principal Investigator
University of Toronto
Eligibility Criteria
This trial is for children aged 18-30 months who are late talkers and primarily English-speaking without vision issues. They must be enrolled at a participating facility, have no MRI contraindications like metal implants or claustrophobia, and not be in special education due to ability or behavior.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive an intervention program addressing late talking, including parent coaching and direct therapy for children, over 6 to 8 weeks.
Follow-up
Participants are monitored for treatment-related changes in language function and structural connectivity.
Open-label extension (optional)
Participants may continue to receive intervention after the main study period.
Treatment Details
Interventions
- Intervention to address late talking (Behavioural Intervention)
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Toronto
Lead Sponsor
Allison Brown
University of Toronto
Chief Medical Officer
PhD in Chemical Engineering from the University of Toronto
Michael Sefton
University of Toronto
Chief Executive Officer since 2017
PhD in Chemical Engineering from the University of Toronto and MIT
Georgetown University
Collaborator
Dr. Ivica Labuda
Georgetown University
Chief Executive Officer since 2022
PhD in Biochemistry and Molecular & Cellular Biology from Slovak Academy of Sciences, University of Graz, and Rutgers University
Dr. Richard Ascione
Georgetown University
Chief Medical Officer since 2023
MD from Georgetown University Medical School
Children's Hospital Medical Center, Cincinnati
Collaborator
Steve Davis
Children's Hospital Medical Center, Cincinnati
Chief Executive Officer since 2021
MD
Daniel Ostlie
Children's Hospital Medical Center, Cincinnati
Chief Medical Officer
MD from University of North Dakota
Holland Bloorview Kids Rehabilitation Hospital
Collaborator
Julia Hanigsberg
Holland Bloorview Kids Rehabilitation Hospital
Chief Executive Officer since 2015
Law degrees from McGill University and Columbia Law School
Dr. Golda Milo-Manson
Holland Bloorview Kids Rehabilitation Hospital
Chief Medical Officer since 2010
MD from University of Toronto
University of Cincinnati
Collaborator
Dr. Greg Postel
University of Cincinnati
Chief Medical Officer since 2020
MD from Indiana University School of Medicine
Dr. Neville G. Pinto
University of Cincinnati
Chief Executive Officer since 2017
PhD in Chemistry from the University of Virginia